Boston Scientific Corporation $BSX Stock Position Raised by Provenance Wealth Advisors LLC

Provenance Wealth Advisors LLC grew its holdings in Boston Scientific Corporation (NYSE:BSX) by 20,140.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 11,537 shares of the medical equipment provider’s stock after acquiring an additional 11,480 shares during the quarter. Provenance Wealth Advisors LLC’s holdings in Boston Scientific were worth $504,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of BSX. Associated Banc Corp purchased a new stake in Boston Scientific during the 3rd quarter worth approximately $24,031,000. Putney Financial Group LLC purchased a new position in shares of Boston Scientific in the third quarter worth $79,000. Integrity Alliance LLC. raised its holdings in shares of Boston Scientific by 20.9% in the third quarter. Integrity Alliance LLC. now owns 7,525 shares of the medical equipment provider’s stock worth $328,000 after buying an additional 1,301 shares during the last quarter. First Nebraska Trust Co acquired a new stake in shares of Boston Scientific during the third quarter worth $4,847,000. Finally, Factory Mutual Insurance Co. lifted its stake in shares of Boston Scientific by 227.0% during the third quarter. Factory Mutual Insurance Co. now owns 276,600 shares of the medical equipment provider’s stock worth $12,074,000 after buying an additional 192,000 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $44.60 on Friday. The company has a current ratio of 1.36, a quick ratio of 0.74 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 12 month low of $39.57 and a 12 month high of $105.65. The company has a 50 day simple moving average of $44.40 and a two-hundred day simple moving average of $55.94. The stock has a market cap of $64.65 billion, a price-to-earnings ratio of 18.90, a PEG ratio of 1.36 and a beta of 0.60.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, meeting the consensus estimate of $0.73. The business had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. The business’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.75 EPS. As a group, analysts predict that Boston Scientific Corporation will post 3.17 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on BSX shares. Sanford C. Bernstein dropped their price objective on shares of Boston Scientific from $54.00 to $49.00 and set an “outperform” rating on the stock in a report on Thursday, October 29th. Rothschild & Co Redburn reduced their target price on Boston Scientific from $106.00 to $78.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Deutsche Bank Aktiengesellschaft set a $48.00 price target on Boston Scientific and gave the stock a “buy” rating in a research report on Thursday, October 29th. JPMorgan Chase & Co. cut Boston Scientific from an “overweight” rating to a “neutral” rating and set a $46.00 price target for the company. in a research report on Wednesday, October 28th. Finally, Evercore dropped their price target on Boston Scientific from $65.00 to $52.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $61.43.

Boston Scientific Company Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.